205876-53-5

Upstream product

• 613-92-3 N-hydroxybenzenecarboximidamide 
• 100-47-0 benzonitrile 
• 54752-10-2 O-(ethoxycarbonyl)benzohydroxamamide 
• 1456-22-0 3-phenyl-4H-[1,2,4]oxadiazol-5-one 
• 109-64-8 1,3-dibromo-propane 

Downstream Products

• 1370330-82-7 methyl 4-(4,5-dihydro-5-oxo-4-(3-(5-oxo-3-phenyl-1,2,4-oxadiazol-4-yl)propyl)-1,2,4-oxadiazol-3-yl)benzoate 
• 1370330-83-8 C₁₈H₂₀N₄O₄ 

Relevant academic research and scientific papers

A novel bifunctional chelating agent based on bis(hydroxamamide) for 99mTc labeling of polypeptides

This paper describes the synthesis and biological evaluation of a novel bifunctional chelating agent (BCA) based on bis(hydroxamamide) for 99mTc labeling of polypeptides. We successfully designed and synthesized C3(BHam)2·COOH as a new BCA. C 3(BHam)2·COOH formed a stable 99mTc complex and enabled us to prepare 99mTc-labeled polypeptides by using a 2,3,5,6-tetrafluorophenol (TFP) active ester of C3(BHam) 2·COOH. 99mTc-C3(BHam) 2·HSA prepared with C3(BHam)2·TFP was stable in both murine plasma and an excess of l-cysteine without any dissociation of 99mTc from polypeptides. Furthermore, the blood clearance of 99mTc-C3(BHam)2·HSA in mice was similar to that of 125I-HSA, suggesting that C 3(BHam)2·COOH retained stable binding between 99mTc and the polypeptides in vivo. When 99mTc-C 3(BHam)2·NGA was injected into mice, the radioactivity showed high hepatic uptake early on and a rapid clearance from the liver, indicating that C3(BHam)2·COOH did not affect the pharmacokinetics of polypeptides in vivo and gave radiometabolites, which displayed a rapid elimination from the liver. Such characteristics would render C3(BHam)2·COOH attractive as a new BCA for 99mTc labeling of polypeptides. Copyright